[已阅读次]
庞建新




姓名:庞建新

职称:教授,博士生导师

邮箱:pjx@smu.edu.cn

电话:020-61648671


 

学习经历:

1984.09-1989.06  湖北医学院咸宁分院临床医学,学士

1992.09-1995.07  第一军医大学药理学,硕士

1999.09-2002.07  第一军医大学药理学,博士


 

科研工作经历:

1995.07-1999.09  第一军医大学,基础部药理学教研室,讲师

1999.09-2004.08  第一军医大学,药理学教研室,讲师

2004.08-2007.08  南方医科大学,药理学教研室,副教授

2007.08-至今     南方医科大学,药学院新药评价/科技开发中心主任,教授


 

承担课程:

1. 本科生课程:《药理学》、《新药评价》、《药事管理学》

2. 研究生课程:《药理学前沿》、《高等药理学》


 

研究方向:

1.抗代谢性疾病药物药理学

2.抗肿瘤药物药理学

3.新药评价


 

获奖情况:

1.用于止血的蛇毒血凝酶制剂,北京市科学技术二等奖,北京市人民政府,2012。

2.国家一类止血新药尖吻蝮蛇血凝酶,中华全国工商联合会科技进步一等奖,2013.12。

 

 

主持科研课题:

1.国家自然科学基金课题,3-(萘-1-甲基取代)吡啶衍生物通过影响肠-肝-肾尿酸转运体GLUT9和URAT1降尿酸作用的分子机制(81974507),2020.1~2023.12.

2.国家自然科学基金课题,hURAT1转运尿酸的活性位点识别及靶向hURAT1选择性抑制剂设计及降尿酸作用的分子机制(81773794),2018.1~2021.12。

3.广州市民生科技攻关计划,一种特异性抑制肾脏尿酸重吸收转运体的降尿酸化合物CDERSMU167#临床前药理毒理学研究 (201903010087)。2019.4.1~2022.3.31。

4.广州市产业技术重大攻关计划,超2亿元大品种--阿莫西林胶囊一致性评价研究,(201802010004)2018.4~2020.3。

5.广东省科技计划项目,特异性排尿酸药物的设计、合成及功能评价(2014A020210013),2015.7~2018.6。

6.广州市科技计划项目,hTERT C197竞争性抑制端粒酶活性抗肿瘤作用研究(2014J4100195),2014.4~2016.3。

7.国家自然科学基金课题,一种新的从尖吻腹蛇蛇毒中分离纯化的具有类凝血酶作用的凝集素样止血作用的分子机制(81273577),2012。

8.国家自然科学基金课题,30672487。基于酵母RNA三杂交的高通量端粒酶特异抑制剂筛选模型的建立及其应用,2008~2011。

9.广东省自然科学基金课题,端粒酶肿瘤相关抗原诱导抗肿瘤免疫作用的研究(No. 32876). 2004~2006。

10.国家自然科学基金课题,作用于端粒酶催化亚基的小分子肽的研究(No. 30000208). 2001.1~2003.12。

11.横向科研课题,HS062降尿酸作用的药效学研究。2018.3

12.横向科研课题,I类新药S-卡维地洛抗心衰作用的药效学研究,2014~2015.

13.横向科研课题,HCA对凝血因子结合和功能的影响,2011年。

14.横向科研课题,化药4类普拉格雷主要药效学试验研究,2011。

15.横向科研课题,化药4类"磷酸替诺福韦酯"临床前安全性评价试验研究,2010年。

16.横向科研课题,HCA止血作用机制的研究,2010。

17.横向科研课题,苏灵治疗脑外科和脊柱外科手术止血有效性及安全性临床研究,2010。

18.横向科研课题,Effect of JNJ-30912364 on DIO-SIZ mice,2009。


 

学术及社会兼职:

1.全国卫生产业企业管理协会转化医学产业分会常务理事,药学与药物经济学评价协作组副组长。

2.中国药理学会抗炎免疫药理专业委员会委员常务委员。

3.广东省药理学会理事。

4.广东省药理学会抗肿瘤专业委员候任主委。

5.广东省药理学会药物筛选与评价专业委员会副主任委员。

6.广东省药理学会药物毒理专业委员会副主任委员。

7.广东省抗癌协会抗肿瘤药理专业委员会。


 

发表的主要科研论文(*为通讯作者):

1. Zhao T, Zhao Z, Lu F, Chang S, Zhang J, Pang J, Tian Y. Two- and three-dimensional QSAR studies on hURAT1 inhibitors with flexible linkers: topomer CoMFA and HQSAR. Mol Divers. 2019 Mar 13. doi: 10.1007/s11030-019-09936-5. [Epub ahead of print]

2. Lv, Jinyan; Liang, Yemei; Zhang, Shiqing; Lan, Qunsheng; Xu, Ziwei; Wu, Xiaoyan; Kang, Lijun; Ren, Jing; Cao, Ying; Wu, Ting; Lin, Kai li; Yung, Ken; Cao, Xiong; *Pang, Jianxin; Zhou, Pingzheng. DCPIB, an inhibitor of volume-regulated anion channels,distinctly modulates K2P channels. ACS Chem Neurosci. 2019 Jun 19;10(6):2786-2793.

3. Ting Wu, Haixin Li, Qunsheng Lan, Ze-an Zhao, Ying Cao, Pingzheng Zhou, Shanhe Wan, Jiajie Zhang, Hong Jiang, *Qun Zhang, *Jianxin Pang. Protective effects of S-carvedilol on doxorubicin-induced damages to human umbilical vein endothelia cells and rats. J Appl Toxicol .2019 Aug;39(8):1233-1244.

4. Zhai LY, Li MX, Pan WL, Chen Y, Li MM1, Pang JX, Zheng L, Chen JX, Duan WJ. In Situ Detection of Plasma Exosomal MicroRNA-1246 for Breast Cancer Diagnostics by a Au Nanoflare Probe. ACS Appl. Mater. Interfaces 2018, 10, 39478−39486.

5. Cao Y, Chen S, Liang Y, Wu T, Pang J, Liu S, Zhou P. Inhibition of hyperpolarization-activated cyclic nucleotide-gated channels by β-blocker carvedilol. Br J Pharmacol. 2018,175(20):3963-3975.

6. Chen SJ, Xu Y, Liang YM, Cao Y, Lv JY, Pang JX, Zhou PZ. Identification and characterization of a series of novel HCN channel inhibitors. Acta Pharmacol Sin. 2019 ,40(6):746-754.

7. Li H, Huang Y, Wu X, Wu T, Cao Y, Wang Q, Qiu Y, Fu W, Zhang Q, *Pang J. Effects of hemocoagulase agkistrodon on the coagulation factors and its procoagulant activities. Drug Des Devel Ther. 2018 ,12:1385-1398.

8. Qin L, Sun ZY, Cheng K, Liu SW, Pang JX, Xia LM, Chen WH, Cheng Z, Chen JX. Zwitterionic Manganese and Gadolinium Metal-Organic Frameworks as Efficient Contrast Agents for in Vivo Magnetic Resonance Imaging. ACS Appl Mater Interfaces. 2017.9(47):41378-41386 .

9. Wang H, Peng Y, Zhang T, Lan Q, Zhao H, Wang W, Zhao Y, Wang X, *Pang J *Wang S, *Zheng J. Metabolic epoxidation is a critical step for the development of benzbromarone-induced hepatotoxicity. Drug Metab Dispos. 2017 .45(12): 1354- 1363.

10. Wu T, Li HX,Chen JS, Cao Y, Fu WM, Zhou PZ, *Pang JX. Apigenin, a novel candidate involving herbdrug interaction (HDI), interacts with organic anion transporter 1 (OAT1). Pharmacol Rep. 2017, 69(6):1254-1262.

11. Wu T, Chen JS, Dong S, Li HX, Cao Y, Tian YX, Fu WM, Zhou PZ, * Xi BM, *Pang JX. Identification and characterization of a potent and selective inhibitor of human urate transporter 1, Pharmacological Reports. 2017.69(5):1103–1112.

12.  Wang SS, Feng L, Hu BG, Lu YF, Wang WM, Guo W, Suen CW, Jiao BH, *Pang JX, *Fu WM, *Zhang JF. miR-133a Promotes TRAIL Resistance in Glioblastoma via Suppressing Death Receptor 5 and Activating NF-κB Signaling. Mol Ther Nucleic Acids. 2017.8:482-492. doi: 10.1016/j.omtn.2017.07.015. Epub 2017 Aug 4. Sep 15;

13. Liu Y, Wang WM, Lu YF, Feng L, Li L, Pan MZ, Sun Y, Suen CW, Guo W, *Pang JX, * Zhang JF. *Fu WM. Usp5 functions as an oncogene for stimulating tumorigenesis in hepatocellular carcinoma. Oncotarget. 2017,8(31):50655-50664.

14. Liu Y, Wang WM, Zou LY, Li L, Feng L, Pan MZ, Lv MY, Cao Y, Wang H, Kung HF, *Pang JX, *Fu WM, *Zhang JF. Ubiquitin specific peptidase 5 mediates Histidine-rich protein Hpn induced cell apoptosis in hepatocellular carcinoma through P14-P53 signaling. Proteomics. Proteomics. 2017,17(12). doi: 10.1002/pmic.201600350.

15.Wu KF, Liang WC, Feng L, Pang JX, Waye MM, Zhang JF, Fu WM. H19 mediates methotrexate resistance in colorectal cancer through activating Wnt/β-catenin pathway.Exp Cell Res. 2017, 350(2):312-317.

16. Cao Y, Pang J, Zhou P. HCN Channel as Therapeutic Targets for Heart Failure and Pain. Curr Top Med Chem. 2016;16(16):1855-61.

17. Wu X, Chen J, Cao Y, Xie B, Li H, Zhou P, Qiu Y, *Pang J. Antitumor effect of COOH-terminal polypeptide of human TERT is associated with the declined expression of hTERT and NF-κB p65 in HeLa cells. Oncol Rep. 2015, 34(6): 2909-2916.

18. Mo DW, Dong S, Sun H, Chen JS, Pang JX, Xi BM, Chen WH. Synthesis and potent inhibitory activities of carboxybenzyl-substituted 8-(3-(R)- aminopiperidin- 1-yl)-7-(2-chloro/cyanobenzyl)-3-methyl-3,7-dihydro-purine-2, 6-diones as dipeptidyl peptidase IV (DPP-IV) inhibitors. Bioorg Med Chem Lett. 2015,25(9):1872-1875.

19. Li YC, He SM, He ZX, Li M, Yang Y, Pang JX, Zhang X, Chow K, Zhou Q, Duan W, Zhou ZW, Yang T, Huang GH, Liu A, Qiu JX, Liu JP, Zhou SF. Plumbagin induces apoptotic and autophagic cell death through inhibition of the PI3K/Akt/mTOR pathway in human non-small cell lung cancer cells. Cancer Lett. 2014. 344(2):239-259.

20. Yu PJ, Ci W, Wang GF, Zhang JY, Wu SY, Xu W, Jin H, Zhu ZG, Zhang JJ, *Pang JX, *Wu SG.. Praeruptorin A inhibits lipopolysaccharide-induced inflammatory response in murine macrophages through inhibition of NF-κB pathway activation. Phytother Res. 2011. 25(4):550-556.2011.

21. Xiao-ping Liu, Ying Cao, Huan-yu Kong, Guang-fai Wang, Wen-feng Zhu, Jia-jie Zhang, Yu-chang Qiu, Jian-xin Pang. Antihyperglycemic and Antihyperlipidemic effect of Uraria crinita Water Extract in Diabetic Mice Induced by STZ and Food. J Med Plan Res, 2010,4(5):370-374.

22. Shu-Ying Gao, En-Min Li, Lei Cui, Xiao-Feng Lu, Ling-Ying Meng, Hua-Min Yuan, Jian-Jun Xie, Ze-Peng Du, Jian-Xin Pang and Li-Yan Xu. SP1 and AP-1 regulate expression of the human gene VIL2 in esophageal carcinoma cells. J Biol Chem, 2009. 284(12):7995-8004.

23. Lin Lv, Shao-Yu Wu, Guang-Fa Wang, Jia-Jie Zhang,*Jian-Xin Pang, *Shu-Guang Wu, *Jin-Jun Rao,Effect of Astragaloside IV on Hepatic Glucose-regulating Enzymes in Diabetic Mice Induced by a High-fat Diet and Streptozotocin. Phytother Res, 2010,24(2):219-224.

24. Wang-fa Wang , Shao-yu Wu , Jin-jun RAO, Lin LV, Wei XU, Jian-xin PANG, Zhong-qiu LIU, Shu-guang WU, Jia-jie ZHANG. .Genipin inhibits endothelial exocytosis via nitric oxide in cultured human umbilical vein endothelial cells. Acta Pharmacol Sin, 2009 30(5):589-96.

 

申请或授权专利:

1. 张嘉杰,田元新,庞建新. 3-(萘-1-甲基取代)(萘-1-甲基取代)吡啶衍生物及其合成方法和应用.20181018272;国际专利(PCT)/CN2018/115184.

2. 陈金香,庞建新,刘叔文,白丽萍,姜志宏。RYSTALLINE CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGING, KIT AND COMPOSITION COMPRISING IT AND THEIR USE. 澳洲发明专利:2016101702;美国发明专利:15271368.

3. 庞建新;习保民;吴婷;陈嘉盛;董帅;王杞妹. 一种能促进尿酸排泄的人体尿酸盐转运体-1抑制剂及其制备方法. CN106008421A.

4. 习保民,王纯叶,江振洲,陈望忠, 庞建新,陈文华, 谢宝平, 曹莹. 一种2,6-二取代哒嗪酮类化合物及其应用.201310257896.7.

5. 习保民;王海全;江振洲;陈望忠;陈文华;庞建新.一种苯基哌嗪哒嗪酮及其制备方法和应用.申请号:201210392666.7.

6. 张嘉杰,王广发,伍小云、吴少瑜、刘中秋、万山河、庞建新、徐伟,游文玮、吴曙光,一种咪唑并吡啶类化合物 CN1011239979,PCT/ CN20081000517.

7. 庞建新;刘晓萍,曹莹,孔焕育,王杞妹,刘中秋,丘玉昌,王广发,张嘉杰. 石参在制备治疗Ⅱ型糖尿病药物中的应用. CN101703566A.

8. 马仁强,庞建新,刘璇,邹红.续断总皂苷及制备和应用.申请号: 200710031558.6.

上一条:陈金香
下一条:徐江平